



## **Angiogenesis, Exudation, and Degeneration 2018**

February 10, 2018  
Mandarin Oriental, Miami, FL

Program Directors: Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD and Thomas A. Albini, MD

### **PROGRAM**

Subject to Change

#### **Saturday, February 10, 2018**

7:00 am      **Registration and Continental Breakfast**

7:55      **Welcome and Overview**  
Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD

#### **Session I: Age-Related Macular Degeneration**

Moderators: Philip J. Rosenfeld, MD, PhD and Thomas A. Albini, MD

- 8:00      Top Innovations in Retina – A VC's Perspective  
**Emmett T. Cunningham, Jr., MD, PhD, MPH**
- 8:10      Rare and High Impact Genetic Variants Related to Macular Degeneration  
**Johanna M. Seddon, MD, SCM**
- 8:20      Risk Factors for Progression to Advanced Age-Related Macular Degeneration: 5-year Follow-up of Patients with Early AMD Forms  
**Carel B. Hoyng, MD**
- 8:30      Oil Spill Strategies for AMD - Proof-of-Concept Studies  
**Christine A. Curcio, PhD, FARVO**
- 8:40      The Gut Feeling in AMD: Analysis of the Intestinal Microbiome in Exudative AMD  
**Sebastian Wolf, MD, PhD**
- 8:50      Drusenoid Detachment of the Retinal Pigment Epithelium: Life Cycle  
**Lawrence A. Yannuzzi, MD**
- 9:00      Computational Models of the Choroid and Outer Retina: Insights into Aging and Disease  
**Philip Luthert, MB BS**
- 9:10      OCTA Imaging of the Choriocapillaris  
**Ruikang Wang, PhD**

9:20 Ultrahigh Speed OCT for Assessing Vascular Impairment  
**James Fujimoto, PhD**

9:30 OCTA Based Clinical Trial Endpoints in AMD  
**Nadia Waheed, MD**

9:40 Geographic Atrophy Secondary to AMD: Baseline Data from Proxima A  
**Nancy M. Holekamp, MD**

### **Session II: Non-Exudative AMD**

Moderators: Harry W. Flynn, Jr. MD and Jaclyn L. Kovach, MD

9:50 Gap Junction (Connexin Channel) Therapy  
**Colin Green, BSc, MSc, PhD, DSc**

10:00 Kamuvudine for Macular Degeneration  
**Jayakrishna Ambati, MD**

10:10 Novel Anti-Oxidants in the Treatment of Intermediate Age-Related Macular Degeneration: The TRIAD Trial  
**Karl G. Csaky, MD**

10:20 Efficacy of Elamipretide, a Mitochondrial-Targeted Drug, in the Treatment of Vision Loss in Drusen and Noncentral GA  
**Scott W. Cousins, MD**

10:30 Macrophage Modulation as Therapeutic Target in Dry AMD  
**Shelley Romaine Boyd, MD, FRCS, DABO, BSc**

10:40 HMR59 -Gene Therapy for Dry AMD – Background and Pre-Clinical Studies  
**Jay S. Duker, MD**

10:50 HMR59 – Gene Therapy for Dry AMD – Initial Results of the Phase 1b Study  
**Elias Reichel, MD**

11:00 C3 Inhibition for Geographic Atrophy in AMD  
**Cedric G. Francois, MD, PhD**

11:10 Increased Exudation after C3 Inhibition: Why SS-OCTA is Necessary for Non-Exudative AMD Clinical Trials  
**Philip J. Rosenfeld, MD, PhD**

### **Session III: Macular Neovascularization: Imaging and Emerging Therapies**

Moderators: Philip J. Rosenfeld, MD, PhD and Ninel Z. Gregori, MD

11:20 Understanding Aneurysmal Type 1 Neovascularization, aka Polypoidal Choroidal Vasculopathy  
**K. Bailey Freund, MD**

11:30 Nascent Type 3 Neovascularization in Age-Related Macular Degeneration  
**Giuseppe Querques, MD, PhD**

- 11:40 Second Generation Gene Therapy for Neovascular AMD  
**Allen C. Ho, MD**
- 11:50 Squalamine Combination Therapy for Exudative AMD – Results of a Randomized Clinical Trial  
**Jason S. Slakter, MD**
- 12:00 Evaluation of Binding Affinity, Stability and Sterility of Aflibercept and Ziv-Aflibercept after Compounding Method  
**Michel E. Farah, MD**
- 12:10 Ang2 Inhibition in Neovascular AMD  
**TBD**
- 12:20 Delayed Intraocular Inflammatory Response Following Intravitreal Injections  
**Stephan Michels, MD, MBA**
- 12:30 **Lunch**

**Session IV: Macular Neovascularization and Anti-VEGF Therapy**

Moderators: Thomas A. Albini, MD and Harry W. Flynn, Jr., MD

- 1:30 IVAN Study: 5-year Follow up Results  
**Usha Chakravarthy, MD**
- 1:40 CNV Long Term Evolution after Treatment  
**Bruno Lumbroso, MD**
- 1:50 Impact of Injection Frequency on Visual Outcomes: a Real-world Analysis  
**Andrew A. Moshfeghi, MD**
- 2:00 Geographic Atrophy Secondary to Anti VEGF Treatment: Data from Real Live Clinical Trials  
**Giovanni Staurenghi, MD**
- 2:10 Outcomes in Patients with Neovascular Age-related Macular Degeneration Based on Dosing Intervals in the Second Year of the VIEW Studies  
**W. Lloyd Clark, MD**
- 2:20 Prognostic Factors for Visual Outcomes in Eyes Treated with Ranibizumab for Myopic Choroidal Neovascularization  
**Diana V. Do, MD**

**Session V: Brolucizumab Symposium**

Moderators: Philip J. Rosenfeld, MD, PhD and Lawrence J. Singerman, MD, FACS

- 2:30 The Science Behind Brolucizumab  
**Carl D. Regillo, MD, FACS**
- 2:40 Brolucizumab Phase 3 Study Design  
**Rishi P. Singh, MD**

- 2:50 Brolucizumab Phase 3 Top Line Results  
**David M. Brown, MD, FACS**
- 3:00 Brolucizumab Phase 3 Analysis of Images and Cases  
**Glenn J. Jaffe, MD**
- 3:10 Brolucizumab Phase 3 Additional Analyses  
**Pravin U. Dugel, MD**
- 3:20 Panel Discussion

#### **Session VI: Retinal Vascular Diseases: Imaging and Anti-VEGF Therapy**

Moderator: Harry W. Flynn, Jr., MD and Justin Townsend, MD

- 3:30 Suspended Scattering Particles in Motion: A Novel OCTA Finding in Exudative Maculopathy  
**Amir H. Kashani, MD, PhD**
- 3:40 Wide Field SS OCT-A: Why We need it for Diabetic Retinopathy  
**Professor Jean-Francois Korobelnik**
- 3:50 Precise Detection of Macular Capillary Nonperfusion Using SS-OCT Angiography in Macular Edema Secondary to Diabetic Retinopathy and Retinal Vein Occlusion  
**Toshinori Murata, MD, PhD**
- 4:00 OCT Angiography and Diabetic Retinopathy  
**Harry W. Flynn, Jr., MD**
- 4:10 Diabetic Retinopathy, Capillary Perfusion and Anti-VEGF Therapy  
**Ramin Tadayoni, MD, PhD**
- 4:20 Mechanism by which VEGF Suppression Improves Retinal Vessel Closure in DME and RVO  
**Peter A. Campochiaro, MD**
- 4:30 Circulating VEGF Levels after Anti-VEGF Therapy in Diabetics  
**Lee M. Jampol, MD**
- 4:40 Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy: 6-Month Outcomes of the Prospective, Randomized RECOVERY Trial  
**Charles C. Wykoff, MD, PhD**
- 4:50 Anti-VEGF in ROP: Safety and Managing Expectations  
**Darius M. Moshfeghi, MD**

#### **Session VII: Diabetes, Retinal Degenerations, and Uveitis**

Moderator: Thomas A. Albini, MD and Philip J. Rosenfeld, MD, PhD

- 5:00 Pharmacotherapy in Development for Diabetic Macular Edema: What May Be Coming to the Clinics?  
**Quan Nguyen, MD, MSc**

- 5:10 Topical Therapy for Diabetic Macular Edema  
**David S. Boyer, MD**
- 5:20 Integrin Antagonism and DME  
**Peter K. Kaiser, MD**
- 5:30 Ang2 Inhibition in Diabetic Macular Edema  
**TBD**
- 5:40 MacTel Phase 2 Trial with CNTF  
**Emily Y. Chew, MD**
- 5:50 Update on Clinical Trials for Retinal Degenerations  
**Byron L. Lam, MD**
- 6:00 Retinal Progenitors Cells for RP: The jCyte Experience  
**Baruch D. Kuppermann, MD, PhD**
- 6:10 Novel Therapies in the Management of Uveitis  
**Sunil Srivastava, MD**
- 6:20 Ocular Histopathologic Features of Congenital Zika Syndrome  
**Sander R. Dubovy, MD**
- 6:30 **Adjourn/Cocktail Reception**